Day 07 of 30 •
•
~4 min read

Understanding High-Grade NEC vs Low-Grade NET

Diving into tumor biology: why Ki-67 index, differentiation, and histology matter so much in neuroendocrine disease.

#neuroendocrine cancer #pathology #high grade nec #oncology #education

In the neuroendocrine cancer community, one of the most critical distinctions patients and caregivers must understand is the difference between a low-grade Neuroendocrine Tumor (NET) and a high-grade Neuroendocrine Carcinoma (NEC). Although they share the ‘neuroendocrine’ name, clinically and biologically they behave like entirely different diseases.

Pathologists classify neuroendocrine neoplasms primarily using two key metrics: differentiation and tumor grade.

Differentiation refers to how the cells look under a microscope.

  • Well-differentiated cells look orderly, organized, and closely resemble normal neuroendocrine tissue.
  • Poorly differentiated cells look chaotic, bizarre, and irregular, having lost the structural characteristics of normal cells.

Grade is determined by how rapidly the cells are dividing, most commonly measured by the Ki-67 proliferation index:

  • Grade 1 (G1): Low proliferation; Ki-67 index less than 3%. Cells divide very slowly.
  • Grade 2 (G2): Intermediate proliferation; Ki-67 index between 3% and 20%.
  • Grade 3 (G3): High proliferation; Ki-67 index greater than 20% (often 60%, 80%, or higher).

This creates two distinct Grade 3 entities that are frequently confused:

  1. Well-Differentiated G3 NET: These are tumors whose cells still look like organized NETs, but have a higher proliferation rate.
  2. Poorly Differentiated G3 NEC: These are true carcinomas, divided into small cell and large cell variants. They are genetically distinct, frequently harboring mutations in TP53 and RB1, and they divide at breakneck speed.

This difference dictates treatment. Patients with low-grade NETs often live for many years or even decades with treatments like somatostatin analogues (octreotide, lanreotide), targeted oral agents (everolimus, sunitinib), or radioligand therapy (Lutathera / PRRT).

High-grade NEC, however, rarely responds to standard NET therapies. It requires aggressive, urgent systemic chemotherapy—frequently platinum-based regimens like carboplatin or cisplatin combined with etoposide—often accompanied by immunotherapy.

When Ana was diagnosed with high-grade NEC, understanding this distinction was essential. It explained why treatments that worked for other neuroendocrine patients were not appropriate for her. Educating patients and doctors about this vital difference saves lives by ensuring patients receive the correct, timely chemotherapy without dangerous delays.

Ana Carolina Medina Castillo
Written in Loving Memory

Ana Carolina Medina Castillo

September 5, 1992 – 2026 • Monterrey, MX & Arlington, TX

Registered Nurse (BSN, UT Arlington), devoted mother of Eliana, Elias, and Elaina, and beloved wife of Josue Negron. Her courage and grace continue to guide this platform to ensure no family faces neuroendocrine carcinoma alone.